A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
Public ClinicalTrials.gov record NCT04530110. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). Secondary objectives are to evaluate the efficacy of subcutaneous fremanezumab in pediatric participants with migraine and to evaluate the immunogenicity of fremanezumab and the impact of ADAs on clinical outcomes in pediatric participants exposed to fremanezumab. The total duration of the study is planned to be up to 84 months.
Study identification
- NCT ID
- NCT04530110
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 499 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 16, 2020 (Actual)
- Primary completion
- Aug 15, 2025 (Actual)
- Completion
- Dec 22, 2025 (Actual)
- Last update posted
- Jul 24, 2026
2020 – 2025
United States locations
- U.S. sites
- 32
- U.S. states
- 23
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 14319 | Aurora | Colorado | 80045 | — |
| Teva Investigational Site 14368 | Colorado Springs | Colorado | 80907 | — |
| Teva Investigational Site 14244 | Jacksonville | Florida | 32256 | — |
| Teva Investigational Site 14325 | Miami | Florida | 33155 | — |
| Teva Investigational Site 14250 | West Palm Beach | Florida | 33407 | — |
| Teva Investigational Site 14255 | West Palm Beach | Florida | 33409 | — |
| Teva Investigational Site 14243 | Atlanta | Georgia | 30328 | — |
| Teva Investigational Site 14258 | Savannah | Georgia | 31406 | — |
| Teva Investigational Site 14263 | Hoffman Estates | Illinois | 60169 | — |
| Teva Investigational Site 14245 | Wichita | Kansas | 67206 | — |
| Teva Investigational Site 14327 | Louisville | Kentucky | 40202 | — |
| Teva Investigational Site 14360 | Covington | Louisiana | 70433 | — |
| Teva Investigational Site 14365 | Baltimore | Maryland | 21201 | — |
| Teva Investigational Site 14246 | Waltham | Massachusetts | 02451 | — |
| Teva Investigational Site 14251 | Ann Arbor | Michigan | 48104 | — |
| Teva Investigational Site 14270 | Minneapolis | Minnesota | 55402 | — |
| Teva Investigational Site 14376 | Ridgeland | Mississippi | 39157 | — |
| Teva Investigational Site 14256 | Bridgeton | Missouri | 63044-2513 | — |
| Teva Investigational Site 14371 | New Brunswick | New Jersey | 08901 | — |
| Teva Investigational Site 14276 | Amherst | New York | 14226 | — |
| Teva Investigational Site 14377 | Durham | North Carolina | 27710 | — |
| Teva Investigational Site 14248 | Raleigh | North Carolina | 27607 | — |
| Teva Investigational Site 14264 | Cincinnati | Ohio | 45229-3039 | — |
| Teva Investigational Site 14257 | Oklahoma City | Oklahoma | 73112 | — |
| Teva Investigational Site 14363 | Tulsa | Oklahoma | 74136 | — |
| Teva Investigational Site 14364 | Philadelphia | Pennsylvania | 19104-4318 | — |
| Teva Investigational Site 14374 | Bristol | Tennessee | 37620 | — |
| Teva Investigational Site 14252 | Austin | Texas | 78731 | — |
| Teva Investigational Site 14273 | Austin | Texas | 78759 | — |
| Teva Investigational Site 14367 | Dallas | Texas | 75235-7701 | — |
| Teva Investigational Site 14375 | Salt Lake City | Utah | 84109 | — |
| Teva Investigational Site 14323 | Norfolk | Virginia | 23510 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04530110, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 24, 2026 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04530110 live on ClinicalTrials.gov.